Is the Day When the Fear of Cancer Disappears Near? The Evolving Treatments and AI Paving the Way for the Future

What Did the Cheers from the Doctors Mean?

Experts filling the venue gave a warm applause to the research presentation on cancer treatment.

An article introducing the science podcast from the German newspaper ZEIT reports such a scene at the ESMO Congress, the academic meeting of the European Society for Medical Oncology held in Madrid in 2026. A similar scene was reportedly observed at a cancer conference in Chicago, USA, a few months earlier.

The presentation introduced mRNA cancer vaccines designed for each patient and drugs that attack cancer through new mechanisms. The article poses the question, "Is cancer gradually losing its terror?"

For patients and their families, there might be no answer they want more. Can recurrence be prevented? If current treatments stop working, are there next options? Can they plan for the next year?

However, the cheers at the conference cannot simply be interpreted as "the era of curing cancer has arrived."

To understand the progress made this time, it is necessary to unravel the large word "cancer" and see what has improved at which stage of which disease.

"Cancer Vaccine" Does Not Necessarily Mean Vaccination for Healthy People

At the center of this topic is the personalized mRNA vaccine being researched for the treatment of melanoma, or malignant melanoma.

When hearing "vaccine," it's easy to imagine something administered before getting sick. However, this research aims to reduce recurrence in people who have already developed cancer and undergone surgery.

The key to understanding the mechanism lies in the genetic changes that occur in cancer cells. Some parts of the abnormal proteins produced by these changes can serve as markers for the immune system to identify cancer. These markers are called "neoantigens."

The patient's tumor is examined, and markers characteristic of that person's cancer are selected. Then, the design information to produce those markers in the body is delivered via mRNA, promoting an immune response that recognizes and attacks cancer cells.

The significant difference is that it is tailored to the characteristics of each individual's tumor, rather than administering the same thing to everyone.

It is not the first time that cancer-related preventive vaccines have appeared. The focus this time is on the progress of mRNA vaccines designed for the patient's own tumor for therapeutic purposes.

How to Interpret "42% Reduction in Recurrence and Death Risk"

The phase III trial "INTerpath-001" introduced by the American Association for Cancer Research examined the effect of adding the personalized mRNA vaccine "intismeran autogene" to the immunotherapy drug pembrolizumab for high-risk melanoma patients who had their tumors surgically removed.

The key reported result was a 42% reduction in the risk of recurrence or death compared to treatment with pembrolizumab alone.

The 42% here does not mean "42% of patients were cured." It indicates how much the risk of recurrence or death was relatively reduced between the compared groups.

According to the explanation from the Memorial Sloan Kettering Cancer Center, which participated in the trial, the two-year recurrence-free survival rate was 82% in the vaccine combination group and 70% in the comparison group. This figure shows the percentage of people who survived without recurrence at a certain point in time.

The relative risk reduction and the difference in percentage at a specific point are different indicators. Looking at both can provide a more concrete understanding of the effect.

Moreover, reducing recurrence and ultimately extending lifespan are not the same question. Evaluation of overall survival continues, and long-term effects need to be verified.

Still, for those living with the anxiety of recurrence after surgery, the potential to reduce recurrence is of great significance. Researchers are hopeful for such concrete improvements.

New Options Have Emerged for Pancreatic Cancer

Another topic covered in the ZEIT article is a drug called daraxonrasib.

On August 26, 2026, the U.S. Food and Drug Administration (FDA) approved this drug for metastatic pancreatic adenocarcinoma in adults meeting certain conditions, including patients who have already undergone systemic therapy.

The drug targets a group of proteins called RAS, which are involved in cancer proliferation. It is one of the molecular targeted therapies that work on mechanisms supporting cancer growth.

In the trial results published by the FDA, the median overall survival for the entire population was 13.2 months in the new drug group and 6.7 months in the comparison group, targeting patients whose condition progressed after prior treatment.

These figures do not predict the lifespan of individual patients. The "median" is an indicator representing the results of the group, and there is variability in actual outcomes.

At the same time, side effects have not disappeared. The FDA has indicated caution regarding skin and oral lesions, diarrhea, and interstitial lung disease.

Nevertheless, the addition of an option that showed improvement in survival time in comparative trials for a difficult-to-treat disease is significant. If we are to speak of hope, it would be more accurate to say, "A treatment that showed better results in a specific patient group has emerged," rather than "Pancreatic cancer has been overcome."

AI Supports the "Candidate Selection" for Treatment

The original article also touches on AI, which accelerates research.

In personalized cancer vaccines, it is necessary to select markers from the vast information obtained from tumors that the immune system is likely to react to. At the National Cancer Institute in the U.S., a machine learning model is being developed to rank neoantigen candidates for vaccine development.

The role of AI in this field is to narrow down the candidates researchers investigate and increase the efficiency of verification.

However, candidates deemed promising by computers do not necessarily work effectively in patients' bodies. It is necessary to verify predictions through experiments and further investigate safety and efficacy in clinical trials.

When evaluating AI progress, it is important to distinguish between "making excellent predictions" and "improving patient treatment outcomes."

The Feelings of Waiting for Approval and Confusion Seen on Social Media

What kind of reactions are appearing on social media in response to such news?

On the overseas forum Reddit, there was a post from someone with a family history of melanoma and personal experience of the disease, expressing a strong desire for the vaccine's approval.

In another thread, a question was posted asking, "Is it both a vaccine and a treatment?" and there was an exchange explaining that this research is a treatment used for people who have already developed cancer.

These are not reactions directly to the ZEIT article but responses to news covering the same treatment research. Additionally, it is not possible to independently verify the medical history of anonymous posters, and these do not represent the opinion of society as a whole.

Nevertheless, this exchange reflects an important issue. As research results become widely known, basic explanations such as "who is the vaccine for" become necessary.

A headline like "Cancer Vaccine Succeeds" alone could lead to the misconception that healthy people can prevent all cancers by getting vaccinated. The higher the expectations for the news, the more important it is to convey the target and purpose without omission.

In the Comments Section of the Original Article, Concerns About Costs and "Overpromising"

Meanwhile, cautious opinions are also published in the reader comments section of the ZEIT article you provided.

One reader reflected on past optimistic outlooks that "cancer can be overcome" and questioned whether the current headline is premature. They also raised the issue of whether public health insurance can cover the costs even if new drugs emerge.

Another reader drew a parallel to the history of resistant bacteria becoming a problem after the widespread use of antibiotics, expressing caution against placing excessive expectations on promising treatments.

However, this comment should not be taken as evidence that cancer treatment worsens the disease. The mechanisms of diseases and treatment conditions differ between infectious diseases and cancer.

It is true that "resistance" to drugs is a challenge in cancer treatment. There may be cells that are less responsive to drugs before treatment begins, or cells that develop resistance during treatment. Therefore, research continues to explore treatment combinations and next options.

Welcoming new treatments and scrutinizing their limitations can coexist. In fact, both perspectives are essential for making treatments useful in the long term.

For Japanese Patients, the Next Issue Is "Can I Receive It?"

When learning about research results overseas, the first concern for Japanese patients and their families is likely, "Can I use it too?"

However, conference presentations, successful clinical trials, overseas approvals, Japanese approvals, and use in insurance-covered medical care are each separate stages.

Even if the vaccine discussed this time has been successful in research, it cannot be judged that it will be immediately available as routine medical care in Japan. The U.S. approval of daraxonrasib does not mean approval or insurance coverage in Japan.

When consulting with your doctor about the news, confirming the following points can help move the conversation forward concretely.

• Does the type and stage of cancer targeted by the research match your situation?
• Is the purpose of the treatment to prevent recurrence after surgery or to suppress advanced cancer?
• What is the approval status in Japan, and are there clinical trials you can consider participating in?
• What are the expected effects and side effects, and what is the burden of visits and costs?

If you don't know where to consult about treatment, life, or finances, you can also use the Cancer Consultation Support Center. According to the National Cancer Center, patients themselves, their families, and people not attending that hospital can consult for free and anonymously.

The value of new treatments is not determined only at the time of discovery. It is necessary to consider whether those who need it can obtain information, have their suitability assessed, and actually reach treatment.

Before Saying "It's No Longer Scary," Convey the Increased Options

The progress of cancer research does not reach all patients at the same speed. Some diseases have new options, while others still have limited effective treatments.

That's why words like "cancer is no longer scary" can leave behind those still facing the difficulty of treatment.

On the other hand, there is no need to underestimate progress. The possibility of reducing postoperative recurrence. The increase in drugs that can be tried if the condition progresses after treatment. These accumulations can change patients' lives and future outlooks.

Translating the cheers at the conference into information for patients. What is needed for that is not the repetition of the word "groundbreaking," but conveying who, what, and how far it has reached.

Hope does not become stronger the more it is magnified. Demonstrating verified achievements alongside unanswered challenges makes hope trustworthy.

Sources and References

1. ZEIT:Reactions at the European cancer conference, interviewed experts, and introduction of related research.
   https://www.zeit.de/wissenschaft/2026-11/krebskongress-europa-forschung-medizin-wissen-podcast

2. National Cancer Institute: Mechanism of mRNA Cancer Vaccines
   Reference material on the mechanism of delivering antigen information via mRNA and promoting immune response. As of the 2022 article, it is not used as a basis for the current development status.NCI
   https://www.cancer.gov/news-events/cancer-currents-blog/2022/mrna-vaccines-to-treat-cancer

3. American Association for Cancer Research: Phase III Trial of Personalized mRNA Vaccine
   Basis for the reduction in recurrence or death risk for melanoma and ongoing evaluation of overall survival.AACR
   https://www.aacr.org/blog/2026/10/26/from-promise-to-proof-personalized-melanoma-mrna-vaccine-delivers-phase-iii-success/

4. Memorial Sloan Kettering Cancer Center: Trial Subjects and Results
   Explanation regarding vaccine personalization, trial overview, and two-year recurrence-free survival rate.Memorial Sloan Kettering Cancer Center
   https://www.mskcc.org/news/promising-results-for-melanoma-mrna-vaccine

5. FDA: Approval Information for Daraxonrasib
   Basis for U.S. approval date, indication, median survival time in comparative trials, and safety precautions.fda.gov
   https://www.fda.gov/drugs/cancer-approvals/fda-approves-daraxonrasib-metastatic-pancreatic-adenocarcinoma

6. National Cancer Institute: Prioritization of Vaccine Candidates by Machine Learning
   Reference material on AI being used to select candidates that the immune system targets.techtransfer.cancer.gov
   https://techtransfer.cancer.gov/available-technologies?abstract=TAB-5023

7. Reddit: Expectations for Melanoma Vaccine
   Source of confirmation for posts expressing a desire for approval, including personal experiences. The content of the posts is self-reported by individuals and is not treated as medical evidence.reddit.com
   https://www.reddit.com/r/Vaccine/comments/1xcdurd/vaccine_for_melanoma/

##HTML